Guidance on the interpretation of faecal calprotectin levels in children

PLoS One. 2021 Feb 11;16(2):e0246091. doi: 10.1371/journal.pone.0246091. eCollection 2021.

Abstract

Background: Faecal calprotectin (FCP) is a powerful tool to predict inflammatory bowel disease (IBD) in patients with gastrointestinal symptoms. In the paediatric patient population, the reference value of < 50 μg/g and the influence of age on FCP levels result in a high number of redundant investigations and specialist referrals. We assessed paediatric FCP levels, their diagnostic value and corresponding referral pathways from primary and secondary care.

Methods: We analysed two cohorts from a precisely defined catchment area: one consisted of all FCPs measured in this area (n = 2788). The second cohort-a subset of the first cohort-consisted of FCP values and corresponding clinical data from children who were referred for possible IBD to our department (n = 373).

Results: In the first cohort, 47% of FCP levels were > 50 μg/g, 15% were ≥ 250 μg/g. Children < 1y had significantly (p < 0.001) higher FCP than older children. In the second cohort, 6.7% of children with an FCP of < 250 μg/g (or 8.6% with an FCP of < 600 μg/g) had IBD-all featured symptoms suggestive of IBD (e.g. bloody diarrhoea, nocturnal abdominal pain, weight loss) or abnormal blood tests. 76% of patients in whom raised FCP (> 50 μg/g) was the sole reason for being referred for suspected IBD did not have IBD.

Conclusion: Children with an FCP < 600 μg/g and without matching symptoms suggestive of IBD are unlikely to have IBD. A higher FCP reference value may provide cost-effective improvement that could avoid redundant investigations and specialist referrals. A guideline for specialist referrals is proposed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age Factors
  • Catchment Area, Health
  • Child
  • Child, Preschool
  • Cohort Studies
  • Early Diagnosis
  • Feces / chemistry*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Inflammatory Bowel Diseases / diagnosis*
  • Inflammatory Bowel Diseases / metabolism
  • Leukocyte L1 Antigen Complex / analysis*
  • Male
  • Practice Guidelines as Topic

Substances

  • Leukocyte L1 Antigen Complex

Grants and funding

MO was funded by the Gottfried-und-Julia-Bangerter-Rhyner foundation (ID 0102/2018). URL: www.bangerter-stiftung.ch FZ was funded by the Swiss National Science Foundation SNF (Grant No: 172198) and the Isaac Newton Trust. www.snf.ch, www.newtontrust.cam.ac.uk The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.